Suven Life Sciences
in its filing to the exchanges informed that the company received product patent from Israel, Japan, New Zealand, and Sri Lanka corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2029, respectively.
Reacting to this, shares of the company gained 3% on the BSE in Thursday's morning trade.
The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds, the company said in a press note after markets hours to the exchanges on Wednesday.
The patents are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Pain, Parkinson Disease and Schizophrenia etc, the company added.
Suven Life Sciences Ltd's share price is currently at Rs263, up by Rs7.6 or 2.98%, from its previous close of Rs255.40 on the BSE.
The scrip opened at Rs261 and has touched a high and low of Rs266.80 and Rs261, respectively. So far, 4,79,221 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs3,250.79cr.